Dr. Timothy Huyck
Claim this profileNebraska Methodist Hospital
Studies Colorectal Cancer
Studies Adenocarcinoma
15 reported clinical trials
31 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Adenocarcinoma
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Timothy Huyck is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Timothy Huyck
Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Timothy Huyck has experience with
- Fluorouracil
- Gemcitabine
- Oxaliplatin
- Irinotecan Hydrochloride
- Leucovorin Calcium
- Nab-paclitaxel
Breakdown of trials Timothy Huyck has run
Colorectal Cancer
Adenocarcinoma
Pancreatic Cancer
Pancreatic Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Timothy Huyck specialize in?
Timothy Huyck focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Timothy Huyck currently recruiting for clinical trials?
Yes, Timothy Huyck is currently recruiting for 5 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Timothy Huyck has studied deeply?
Yes, Timothy Huyck has studied treatments such as Fluorouracil, Gemcitabine, Oxaliplatin.
What is the best way to schedule an appointment with Timothy Huyck?
Apply for one of the trials that Timothy Huyck is conducting.
What is the office address of Timothy Huyck?
The office of Timothy Huyck is located at: Nebraska Methodist Hospital, Omaha, Nebraska 68114 United States. This is the address for their practice at the Nebraska Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.